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ABSTRACT OF THE DISSERTATION
Linking Neuronal Protein Phosphatase 2A to the DLK Stress Kinase Signaling Cascade
by
Margaret Hayne
Doctor of Philosophy in Biology and Biomedical Sciences
Neurosciences
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Professor Aaron DiAntonio, Chair
Neurons are constantly responding to internal and external cues as they adapt through
signaling cascades and transcriptional programs. I have identified a role for the dual leucine
zipper kinase (DLK) and the transcriptional program it controls in neuronal inhibition of the
protein phosphatase PP2A. PP2A is an essential phosphatase, expressed in all cell types and
required for survival. There is a reduction in PP2A activity in Alzheimer’s disease patient brains
which is linked to increased phosphorylation of the microtubule associated protein Tau and
ultimately cell death. Here, I have demonstrated that PP2A acts to restrain the DLK stress
response and that DLK signaling is required for both developmental and degenerative
phenotypes from PP2A inhibition. At the Drosophila neuromuscular junction loss of PP2A
activity causes synaptic overgrowth which requires DLK signaling and induction of a
downstream transcriptional response. Further, DLK is also required for neuronal cell death
following PP2A inhibition in mammalian cortical neurons in vitro. Importantly, DLK signaling
does not affect the phosphorylation of Tau and, indeed, this neuronal cell death is demonstrated
to be a Tau-independent process. Hence, loss of PP2A function triggers two independent

vii

neuropathologies: 1) Tau hyperphosphorylation and 2) DLK activation and subsequent neuronal
cell death.

viii

Chapter 1: Introduction
Neurons are post-mitotic cells, meaning that they must survive for the entirety of an
organism’s lifespan as they will not be replaced through cell division. To do this, they must sense
both internal and external cues and respond appropriately. This sensing and the downstream
responses are often carried out by signaling cascades which converge with either post-translational
modifications to proteins or transcriptional alterations, increasing or decreasing transcription of
target genes. Here, I will explore the links between a protein phosphatase and the activation of a
stress signaling cascade in both peripheral and central neurons, with implications for disease
treatment.

1.1 DLK controls a neuronal stress signaling cascade
The mitogen-activated protein kinase kinase kinase (MAP3K) dual zipper leucine kinase
(DLK) plays an evolutionarily conserved role in neuronal development. In C. elegans DLK is
referred to as DLK-1 and the Drosophila ortholog is called Wallenda (Wnd)(Collins et al., 2006;
Nakata et al., 2005). DLK as a MAP3K activates MAP2Ks, in this case MKK4 and MKK7, and
the MAP kinase Jun-activated N-terminal kinase (JNK)(Walker et al., 2017). This cascade
ultimately activates the transcription factors Fos and Jun when turning on a transcriptional program
in the cell body(Collins et al., 2006).
Knockdown of DLK in cultured primary cortical neurons resulted in decreased extension
of neurites(Eto et al., 2010). DLK knockout mice also displayed defects in the developing cortex,
thought to be linked to a similar mechanism(Hirai et al., 2006). Because migrating neurons travel
along an extended axon to their final location in the cortex, it is thought that the improper axon
extension in DLK knockdown explains the defects in neuronal migration in DLK knockout mice.
1

While there are some effects of DLK and its orthologues in development, the best-studied
role for DLK is in neuronal stress responses. DLK is typically activated in the axons, long
processes extending from the cell bodies which must be maintained and respond appropriately
when injured(Asghari Adib et al., 2018). Upon activation, DLK sends a retrograde signal to the
cell body, where a transcriptional program is activated(Xiong et al., 2010a). This transcriptional
program depends on the organism, cell type, and severity of DLK activation(Asghari Adib et al.,
2018; Collins et al., 2006; Watkins et al., 2013).

1.1.1 Regeneration
In the peripheral nervous system, DLK signaling in an injured neuron tends to be proregenerative. An injured neurite will attempt to grow outward and reform synaptic connections
following an injury, which requires a DLK-dependent transcriptional program to be activated. In
C. elegans with axons severed by lasers, there are no growth cones observed in DLK-1 mutant
animals 5 days after injury while wildtype animals have observable growth cones only 24 hours
following laser axotomy(Hammarlund et al., 2009a). In Drosophila peripheral nerve injury
requires DLK for increased axonal sprouting following injury. This pinch injury, which injures the
nerves in an intact larva, also induces a DLK-dependent transcriptional program, measured using
a LacZ enhancer trap for the phosphatase puckered (PucLacZ)(Xiong et al., 2010b). This role for
regeneration is conserved in mammals, wherein mice lacking DLK in neurons with crushed sciatic
nerves show reduced growth three days after injury compared to wildtype animals(Shin et al.,
2012a). Additionally, when a neurite is injured, the neuron turns on a DLK-dependent
transcriptional program that dramatically enhances regrowth following a second injury in both
flies and mammals(Frey et al., 2015).

2

1.1.2 Degeneration
When a neurite is injured the distal axon degenerates and the proximal axon is able to
regenerate. Both of these processes involve DLK signaling. The olfactory neurons in adult
Drosophila extend into the antennae, which as an exterior structure can be easily removed, and the
axons extending into the brain can be imaged for degeneration. Loss of DLK/Wnd in these flies
inhibits olfactory neuron axon degeneration for 24 hours, by which time wildtype axons have
degenerated significantly(Miller et al., 2009). Dorsal root ganglion (DRG) neurons cultured from
mouse embryos also display delayed axon degeneration following an insult, either a cut to sever
the axons from the cell body or treatment with the chemotherapeutic vincristine, that was delayed
in neurons from DLK mutant animals(Miller et al., 2009).
DLK activation is also required for neuronal cell death in a number of contexts. Embryonic
DRG neurons undergo apoptosis following nerve growth factor (NGF) withdrawal in culture, but
do not die if they lack DLK(Ghosh et al., 2011). Neuronal knockout of DLK also blocks cell death
in retinal ganglion cells following a crush injury to the optic nerve and excitotoxicity models
following kainic acid injections in the mouse brain(Pozniak et al., 2013b; Watkins et al., 2013;
Welsbie et al., 2019).

1.1.3 Development
DLK can be activated extraneously during development, leading to a host of aberrations in
the nervous system. An overabundance of DLK-1 in C. elegans causes alterations in the synaptic
structure, seen by a reduction in the number of presynaptic synaptobrevin puncta as well as changes
to their clustering patterns(Collins et al., 2006; Nakata et al., 2005). In Drosophila, increased
DLK/Wnd activity leads to overgrowth of the presynaptic nerve terminal at neuromuscular
junctions, changes to trans-synaptic machinery, reduced dendritic arborization, and mistargeting
3

of axons in the central nervous system(Collins et al., 2006; Goel and Dickman, 2018; Shin and
DiAntonio, 2011). These changes are thought to result from the DLK stress signaling cascade
being activated in an otherwise healthy neuron, triggering a regeneration response which alters the
structure of the cells.

1.1.4 Disease
The DLK stress pathway has been shown to have increased signaling and deleterious
effects in several disease models. DLK/Wnd has also been demonstrated to be a key modulator of
pathology in a fragile X syndrome Drosophila model. This is a developmental disease wherein
patients display intellectual disability from impaired activity of an RNA repressing protein which
was found to repress DLK/Wnd expression as a key target(Russo and DiAntonio, 2019). The
dysregulation of transactive response DNA binding protein 43 (TDP-43) is a common feature of
amyloid lateral sclerosis (ALS), a progressive neurodegenerative disease. In flies overexpressing
TDP-43, neurodegeneration is blocked by a reduction in Wnd/DLK levels, although a complete
knockout of Wnd/DLK enhances neurodegeneration(Zhan et al., 2015).
Aberrant DLK activation is also observed in mammalian models of neurodegenerative
disease. Subarachnoid hemorrhage in rats causes cell death and behavioral deficits which are
reduced in animals with reduced DLK. An increase in DLK expression following subarachnoid
hemorrhage was also observed, indicating that the insult triggered an aberrant increase in DLK
signaling which contributed to pathology(Yin et al., 2017). In mice expressing PS2APP, presenilin
2 (PSEN2) and amyloid precursor protein (APP), TauP301L, or superoxide dismutase 1 with a G93A
mutation (SOD1G93A), all of which are human genes with disease-linked mutations for Alzheimer’s
disease (PS2APP and TauP301L) or ALS (SOD1G93A) there is an increase in DLK signaling and
downstream phenotypes are DLK-dependent. These mice show increased cell death, impairment
4

in behavioral assays, and an increase in phosphorylation of the transcription factor Jun (p-Jun), a
readout of cellular stress. Neuronal knockdown of DLK in all three of these neurodegenerative
disease models blocked cell death, improved behavior readouts, and reduced levels of p-Jun. The
increase in p-Jun indicates that these disease models are increasing DLK signaling, which is
corroborated by an increase in p-Jun and p-JNK in the central nervous systems of ALS and AD
patients(Le Pichon et al., 2017). Taken together, these studies suggest that DLK presents a
druggable target for multiple neurodegenerative diseases.

1.1.5 Control and Activation
The deleterious effects of overactivation of DLK signaling imply the need for a tight
control of this signaling cascade. DLK levels are restrained by ubiquitination and subsequent
protein degradation through the PHR (Pam/highwire/RPM-1) family of E3 ubiquitin
ligases(Collins et al., 2006; Nakata et al., 2005). These ligases form complexes into an SCF
ubiquitin ligase containing a single protein each from the cullin, SKP1, and f-box protein
families(Brace et al., 2014). In worms, regulator of presynaptic morphology 1 (RPM-1) is a
ubiquitin ligase that targets DLK-1 for degradation, animals mutant for RPM-1 have an
overabundance of DLK-1 which is results in altered synaptic formation(Nakata et al., 2005).
Drosophila Highwire (Hiw) similarly targets Wnd for degradation and mutants display synaptic
and axonal phenotypes(Collins et al., 2006). PHR1, the mouse homologue of human Pam, -mutant
mice have disrupted synapse formation that results in failure to properly form synapses through
the phrenic nerve onto the diaphragm, leading to lethality with mice being unable to
breathe(Burgess et al., 2004). Loss of other components of the SCF complex forming the ubiquitin
ligase also result in altered synaptic development, such as SKPA identified as the key SKP1
orthologue for these processes in the Drosophila nervous system(Brace et al., 2014). DLK stability
5

is also modulated by the chaperone protein HSP90 in flies and mice, as well as by post-translational
modifications including palmitoylation(Holland et al., 2016; Karney-Grobe et al., 2018).
PHR complexes also target Nicotinamide Nucleotide Adenylyltransferase 2 (NMNAT2)
for degradation(Xiong et al., 2012). NMANT2 has been defined to play an important role in the
SARM1-mediated axon degeneration pathway as a labile protein that converts NMN to NAD, an
essential ratio to maintain in order to keep SARM1 in an inhibited state(Figley et al., 2021; Gerdts
et al., 2016). Additionally, high levels of NMNAT2 in Drosophila hiw mutants alter presynaptic
release while having no effect on gross presynaptic morphology(Russo et al., 2019). These links
between PHR proteins, NMNAT2, and DLK were further defined by Walker, et al. through
demonstration that increased DLK activity also decreases NMNAT2 levels(Walker et al., 2017).
These intertwining effects of PHR proteins on DLK and NMNAT2 and between DLK and
NMNAT2 themselves continues to be a rich area of research, exploring how exactly these
pathways contribute to axon degeneration and neuronal development.
Endogenous DLK has been shown to be activated not only by direct insults to neurites,
such as axotomy, but also by dysregulation of the cytoskeletal structure. Treating cultured DRG
neurons with either nocodazole, a drug that destabilizes microtubules, or cytochalasin D, which
affects actin polymerization, results in an increased p-Jun in cell bodies. This is a DLK-dependent
process, as neurons without DLK do not show this increase. The pharmaceuticals only increased
DLK signaling when placed on neurites, treating the cell bodies had no effect on p-Jun
levels(Valakh et al., 2015a). This effect of DLK activation following cytoskeleton disruption has
also been demonstrated genetically in Drosophila, where mutation of the spectraplakin short stop,
which acts to coordinate microtubules and actin – a process that will be discussed more thoroughly
in the next section, or T-complex protein-1 (TCP-1) proteins, chaperone proteins for both tubulin
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and actin, causes DLK-dependent synaptic overgrowth(Valakh et al., 2013). Neither of these
manipulations affect DLK levels, but there is a change in downstream transcriptional program
activation. Together, these studies demonstrate two cases in which altering the cytoskeleton of
neurons activates a DLK-dependent transcriptional program responsible for downstream
phenotypes and imply that other manipulations to the cytoskeleton will also activate DLK
signaling in a potentially deleterious manner.

1.2 Neuronal Cytoskeleton
The cytoskeleton is a dynamic structure that is constantly changing to function with a cell.
During neuronal development the actin, microtubule, and neurofilament structure is necessary
for proper structural support, neurite outgrowth, and organization of synaptic
connections(Akhmanova and Steinmetz, 2010; Desai and Mitchison, 1997; Kapitein and
Hoogenraad, 2015). DLK and PP2A, proteins highlighted in the other sections of this
introduction, both interact with and are influenced by the neuronal cytoskeleton. Hence, here I
will give a brief overview of cytoskeleton form and function in neurons.

1.2.1 Building microtubule structure
Microtubules are a polymerized tube of polarized tubulin dimers, with a dynamic plus-end where
dimers are added or removed under control of microtubule associated proteins
(MAPs)(Akhmanova and Steinmetz, 2015). The constant growth and retraction of microtubules
allow for exploration in space and retraction if a suitable environment is not found. Free tubulin
binds GTP, which is hydrolyzed upon incorporation into the polymer structure. Because of this
there is a GTP cap at the plus end of microtubules, where there is an abundance of recently
incorporated tubulin that has not yet hydrolyzed the GTP to GDP(Kapitein and Hoogenraad,
2015). Plus-end tracking proteins (+TIPS) localize to the plus-end of microtubules and include
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both end-binding (EB) proteins, which have intrinsic +TIP abilities, and other proteins that
associate with EB proteins rather than the plus-end itself(Honnappa et al., 2009).
Because neurons are post-mitotic cells, proteins involved in centromere formation for cell cycle
progression are instead sequestered in the cytoplasm and play a role in nucleation of neurite
microtubules(Kuijpers and Hoogenraad, 2011). Existing microtubules can also be severed to
create new microtubule structures by one of three major groups microtubule severing enzymes,
katanin, spastin, or fidgetin. These proteins are important for neurite branching and outgrowth,
similar processes to those observed in DLK-dependent axon regeneration(Mcnally and RollMecak, 2018). Indeed, Katanin depletion in Drosophila neurons results in an increase in the
number of synaptic boutons at the larval NMJ(Yu et al., 2008).

1.2.2Maintaining microtubule structure
There are four major types of MAPs, EB proteins, +TIPs, -TIPs, and MAPs which bind to
polymerized microtubules and help maintain their stability(Desai and Mitchison, 1997). Tau, and
other structural MAPs which fall into this fourth category such as MAP1 and MAP2 bind to
microtubules and help to prevent microtubule catastrophe and depolymerization. Sequestration
of these proteins in the cytoplasm increases depolymerization events(Rolls et al., 2021).
Interestingly, all three of these proteins are targets of PP2A which will be discussed in the next
section.

1.2.3 Membrane-associated periodic structure
Coordination between actin and microtubules has long been appreciated as important for
extending neurites, but since the advent of stochastic optical resolution microscopy scientists
have been able to study the unique, repeating structure formed by actin and cytoskeletal proteins
in axons. This structure, made up of actin and associated proteins repeats in regular periods along
8

the length of the axon(Xu et al., 2013). A similar structure had been previously defined in
erythrocytes, involving spectrin, ankyrin, and adducin proteins(Baines, 2010; Bennett and
Baines, 2001). In neurons, this repeating pattern, termed the membrane-associated periodic
structure appears to be axon-specific(Xu et al., 2013).
Interestingly, ankyrin, alpha- and beta-spectrin, and adducin, all proteins that are configured in
this period actin structure, also show synaptic defects at the Drosophila NMJ when they are
dysregulated. Loss of presynaptic adducin at the fly NMJ triggers synaptic overgrowth, as well
as signs of synaptic retractions which indicated a neuronal dying-back phenotype(Pielage et al.,
2011). Loss of Ankyrin 2 in fly neurons also leads to retractions, but overexpression causes
synaptic overgrowth and an increase in extraneous satellite boutons(Pielage et al., 2008). Loss of
either presynaptic alpha- or beta-spectrin at the NMJ also causes retractions and disorganization
of microtubules(Pielage et al., 2005). Taken together, alterations to the synaptic structure, a
dysregulation of the cytoskeleton, and neurodegeneration all provide clear links to DLK
signaling. These patterns of synaptic dysregulation that appears similar to aberrant DLK
signaling hints that DLK may be sensitive to loss of the membrane-associated periodic structure
in axons.

1.3 Protein Phosphatase 2A
Protein phosphatase 2A (PP2A) is an essential protein expressed in every cell in the
body(Taleski and Sontag, 2018). Here, I will describe the basic biological processes PP2A is
involved in, a more in-depth exploration of roles PP2A plays in neurons, and will end by discussing
the links between PP2A and microtubule associated protein Tau and Alzheimer’s disease. In my
thesis work I have tested the hypothesis that one of the crucial roles of PP2A in neurons is to
restrain the DLK stress signaling cascade and that when this restraint is lost that DLK-dependent
9

processes will contribute to some of the deleterious effects of PP2A inhibition discussed in this
section.

1.3.1 PP2A biology
Cells use post-translational modifications to regulate protein localization and activation.
One of these common post-translational modifications is phosphorylation, which is added to a
protein via kinase activity and removed through a phosphatase, such as PP2A. PP2A is a
holoenzyme consisting of three subunits, a catalytic subunit (PP2A-C), as well as an A and a B
regulatory subunit. PP2A activity is controlled not only by regulatory subunits, but also by posttranslational modifications(Janssens and Goris, 2001). Phosphorylation of PP2A inhibits activity,
although PP2A appears to be capable of auto-dephosphorylation following these events(Chen et
al., 1992). The catalytic subunit of PP2A can also be methylated to decrease substrate binding,
with a methyl group being added by leucine carboxyl methyltransferase 1 (LCMT-1) and removed
by protein phosphatase methyl transferase (PME-1)(Park et al., 2018; Sontag et al., 2004).
A complete loss of PP2A function is lethal, as PP2A is required for cell division.
Drosophila mutant for PP2A-C cannot exit mitosis and display condensed chromosomes, an
overabundance of centromeres, and disorganized microtubule spindles(Snaith et al., 1996). In
Xenopus eggs this mitotic disorganization was expanded on and better defined to be the result of
hyperphosphorylation of the microtubule associated protein Stathmin(Cormier et al., 1991). PP2A
subunits have been shown to be dysregulated in a number of cancers and are thought to provide a
potential target for chemotherapies(Janssens and Goris, 2001).

1.3.2 PP2A in neurons
PP2A is highly expressed in the brain, even after the point in development when expression
decreases in other tissues. Activity has been studied through both genetic manipulations and
10

pharmaceutical treatments. One of the most common chemical inhibitors of PP2A is okadaic acid
(OA), but other protein phosphatases are inhibited along with PP2A so in the work discussed in
Chapter 2 of this thesis I will use an alternative, more specific chemical inhibitor as well as test
whether genetic inhibition of a related phosphatase give similar phenotypes as a control for any
contamination of function in previous reports(Janssens and Goris, 2001).
Cytoskeleton interactions
In neurons PP2A is strongly associated with the cytoskeleton, directly binding
microtubules as well as modulating the activity of cytoskeleton-modifying proteins. PP2A directly
binds purified tubulin, especially associating with microtubules that have been polymerized. This
association leads to a reduction in PP2A activity compared to PP2A localized to the cytosol.
Inhibition of PP2A activity leads to a reduction in microtubule stability and ultimately
degeneration of the axon, likely through increased phosphorylation of MAPs as these are major
PP2A substrates in neurons(Sontag et al., 1999). Taken together, these data support a model
wherein stable microtubules create a negative feedback loop such that PP2A is less active and
ultimately the microtubules will become less stable following increased phosphorylation of MAPs.
PP2A will then detach from the depolymerizing microtubules, becoming available to act on MAPs
in the cytosol to increase microtubule stability. This loop helps maintain the cytoskeleton as a
dynamic cellular structure, constantly extending and retracting.
PP2A also helps to regulate the transport and function of neurofilaments. Neurofilament
proteins make up a large portion of the structure in the axonal compartment, with some studies
estimating that they make up more than 60% of the protein in the axoplasm. Neurofilaments
interact with microtubules to coordinate the structural support and asymmetric organization of the
cytoskeleton in the complex architecture of neurites. PP2A targets neurofilaments and purifies
11

with neurofilaments in white matter lysates. Hyperphosphorylation of neurofilaments following
PP2A inhibition with OA disrupts anterograde transport of neurofilaments and disrupts axonal
cytoskeletal structure(Saito et al., 2002; Strack et al., 1997).
Microtubule associated proteins
PP2A directly binds MAPs as substrates, including the microtubule stabilizing proteins
MAP2 and Tau(Janssens and Goris, 2001; Sontag and Sontag, 2014). PP2A specifically targets
MAP2 at threonine 220, a common target of protein kinase A (PKA). When MAP2 is
dephosphorylated at this site, it binds microtubules significantly more than when
phosphorylated(Alexa et al., 2002). PP2A also binds to the microtubule binding region of MAP2,
indicating that it specifically targets cytosolic substrate rather than that bound to and stabilizing
microtubules(Sontag et al., 2012). Thus, PP2A activity on MAP2 promotes cytoskeletal stability
through increased binding of MAP2 to microtubules following dephosphorylation.
MAP1B is highly phosphorylated at a defined group of sites by proline-directed protein
kinases during axonal elongation in development, but is then dephosphorylated following
synaptogenesis(Ulloa et al., 1993). MAP1B is also phosphorylated at a second set of sites later in
development by casein kinase II to modulate neuron outgrowth and microtubule dynamics(Gong
et al., 2000b). Both sets of phosphorylation sites on MAP1B are efficiently targeted by PP2A
despite interacting with different kinases and at different points in development.
PP2A targets the MAP doublecortin, a key modulator of axon outgrowth. Doublecortin
localizes to the growing neurite tips and loss of Doublecortin results in unregulated migration of
cortical neurons. Human mutations in Doublecortin cause the developmental disorder X-linked
lissencephaly, associated with mental retardation and seizures. Inhibition of PP2A in vitro leads to
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dissociation of Doublecortin from the extending process of neurites, indicating dephosphorylation
of Doublecortin is a key mechanism in localization(Schaar et al., 2004).
Inhibition of PP2A in developing neurons leads to deleterious effects. Our lab has
established that loss of PP2A function in Drosophila larval neurons causes synaptic overgrowth
and dysregulation of active zone development(Viquez et al., 2009). Viquez et al., went on to
demonstrate that the glycogen synthase kinase 3β (GSK-3β) acts antagonistically to PP2A in these
phenotypes and that PP2A inhibition is affecting the neuronal cytoskeleton. The authors
hypothesized that these changes were the direct result of cytoskeletal dysregulation, but in Chapter
2 I will test the alternative hypothesis that PP2A inhibition activates a DLK-dependent
transcriptional program required for the downstream phenotypes.

1.3.3 PP2A, Tau, and Alzheimer’s disease
Alzheimer’s disease (AD) is the most common form of dementia. It is characterized by
extracellular amyloid beta plaques and abnormally phosphorylated forms of the MAP Tau in
intracellular aggregates. Both of these proteins have been highly studied for pharmaceutical
treatments that reduce their pathological formation or levels of the proteins themselves. Tau is a
well-defined target of PP2A wherein loss of PP2A leads to hyperphosphorylation of Tau(Sontag
and Sontag, 2014). Here, I will discuss the effects of lowered PP2A activity in AD patients with
the implication that targeting a pathway downstream of this to reduce these effects provides a
therapeutic target worthy of further investigation.
Tau function and phosphorylation
Tau is a microtubule associated protein that helps to stabilize the cytoskeleton. The
phosphorylation status of Tau modulates its function, with a lower number of phosphorylation
sites being bound to and stabilizing microtubules while hyperphosphorylated Tau, as observed in
13

AD, is sequestered in the cytoplasm and forms paired helical filaments (PHF) that ultimately
contribute to intracellular tangles(Merrick et al., 1997). Tau binds to microtubules with C-terminal
microtubule-binding motifs while the N-terminal projects into the cytoplasm to interact with
MAPs or the plasma membrane. Tau is phosphorylated by multiple kinases, including GSK-3β,
cdk5, PKA, and CaMKII at defined amino acid residues(Martin et al., 2011). The major
phosphatase affecting these residues is PP2A, accounting for over 70% of Tau phosphatase activity
in the human brain(Liu et al., 2005). Importantly, PP2A is highly efficient at dephosphorylating
the pathogenic site serine 262, which will be used as a readout of Tau hyperphosphorylation in
Chapter 2.
PP2A inhibition in Alzheimer’s disease
There is a significant decrease in PP2A activity in AD patients, thought to contribute to the
hyperphosphorylation of Tau. In one study of homogenate from patient brains there was a roughly
20 to 40% drop in phosphatase activity modulating Tau status compared to control brains(Gong et
al., 1995). When examining protein levels of PP2A in patient homogenate Sontag et al. found a
decrease in the frontal and temporal cortex of AD patients compared to controls but did not find
any changes in PP2A levels in the cerebellums of patient brains. These changes in protein levels
correlate with decreased PP2A activity from patient brain homogenate(Sontag et al., 2004). The
catalytic subunit of PP2A was found to be significantly lowered in a cDNA library of the cingulate
cortex and amygdala tested by microarray as well as in mRNA levels in the hippocampus for AD
patient brains compared to controls(Loring et al., 2001; Vogelsberg-Ragaglia et al., 2001a).
PP2A function is also inhibited in AD through changes in regulatory proteins affecting
PP2A activity. In Situ hybridization for I1PP2A and I2PP2A, endogenous inhibitors of PP2A
activity, show a significant increase in expression in AD patients. This study went on to find an
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increased co-localization of I2PP2A with PP2A and hyperphosphorylated Tau in the temporal
cortex of AD brains, indicating that PP2A inhibition is linked with hyperphosphorylated Tau in
disease(Tanimukai et al., 2005). The PP2A methyltransferase (PPMT) targets the catalytic subunit
of PP2A and methylation of this subunit is required for functional holoenzyme assembly. In AD
brains there is a decrease in PPMT protein levels and a correlated decrease in PP2A-C methylation.
This decrease in both PPMT protein and unmethylated PP2A-C is highest in brain regions that
show the largest increases in hyperphosphorylated Tau. The E3 ubiquitin ligase MID1 targets the
PP2A-interacting protein α4 for ubiquitination. Monoubiquitination of α4 increases cleavage and
the resulting fragment enhances PP2A-C degradation. Levels of cleaved α4 are significantly
increased in AD temporal cortices, suggesting that MID1 and α4 may play a part in the mechanism
lowering PP2A-C levels in AD and ultimately altering the phosphorylation status of Tau(Watkins
et al., 2012a). Cancerous inhibitor of PP2A (CIP2A) is expressed at higher levels in AD patient
brains than controls, and when cultured neurons overexpress CIP2A there is a decrease in PP2A
activity and subsequent increase in Tau hyperphosphorylation and synapse degeneration.
Overexpression of CIP2A in the mouse hippocampus via AAV leads to cognitive impairments as
measured by novel object recognition and Morris water maze tasks and reductions in long term
potentiation(Shentu et al., 2018).
Pharmaceutical and genetic inhibition of PP2A has been used to model aspects of AD
pathogenesis both in vivo and in vitro. Treating primary rat hippocampal neurons with PP2A
inhibitors OA or Calculin A reduces the number of synapses observed on dendrites, causes the
accumulation of vesicles in the axonal compartment, and increases the levels of
hyperphosphorylated Tau(Malchiodi-Albedi et al., 1997). Infusion of OA into the ventricles of the
rat brain increases levels of hyperphosphorylated Tau, amyloid beta deposition, cytoskeletal
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disorganization, and apoptosis(Arendt et al., 1998). Rats with calculin A injected into their
hippocampus developed hyperphosphorylated pathology and had impaired spatial memory as
measured by a Morris water maze(Sun et al., 2003). These pharmaceutical studies are supported
by genetic manipulations to lower PP2A activity also increasing hyperphosphorylated Tau levels,
including a mouse model expressing a dominant negative form of PP2A-C or genetic nulls for one
of the B’ regulatory subunits of PP2A(Kins et al., 2001; Louis et al., 2011). Taken together, these
studies provide evidence that PP2A inhibition is sufficient to recapitulate a portion of the
pathology associated with AD patients, including hyperphosphorylation of Tau, the primary focus
of many studies, as well as increased neuronal cell death, synaptic loss, behavioral deterioration,
and memory impairment.

1.4 Summary
This introduction has summarized findings about the stress kinase signaling cascade
controlled by DLK in neurons, the role and modulation of the cytoskeleton in neurons, and the
protein phosphatase PP2A in development and disease. I aim to address the question of whether
there are other modulators of the cytoskeleton, in this case PP2A inhibition, which activate a DLKdependent transcriptional response. In this thesis I test the hypothesis that the deleterious
downstream effects of PP2A inhibition require activation of the DLK cascade and ask whether
blocking DLK signaling is sufficient to ameliorate these outcomes. These findings have
implications for Alzheimer’s disease, where patients display a decrease in PP2A activity and
hyperphosphorylation of Tau. My work demonstrates that PP2A acts to restrain DLK signaling in
the Drosophila peripheral nervous system, inhibiting synaptic overgrowth and induction of a
transcriptional stress response, as well as in mammalian cortical neurons where cell treated with
PP2A inhibitor undergo DLK-dependent cell death. Importantly, the increased phosphorylation of
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Tau does not require DLK and the cell death following PP2A inhibition is a Tau-independent
process.
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2.1 Abstract
Protein phosphatase 2A (PP2A) is a major cellular phosphatase required for neuronal
survival. PP2A activity is impaired in Alzheimer’s disease, contributing to hyperphosphorylation
of its substrate Tau. Hyperphosphorylated Tau is toxic, and so PP2A is thought to promote
neuronal survival via dephosphorylation of Tau. Here we identify a Tau-independent function of
PP2A required for survival of mammalian cortical neurons. We demonstrate that PP2A inhibits
activation of the neuronal stress kinase DLK and its Drosophila ortholog Wallenda. In the fly,
PP2A inhibition activates a DLK/Wallenda-regulated transcriptional program that induces
synaptic terminal overgrowth at the neuromuscular junction. In cultured mammalian neurons,
PP2A inhibition activates a DLK-dependent apoptotic program. In the absence of Tau, PP2A
inhibition still activates DLK and induces neuronal cell death, demonstrating that
hyperphosphorylated Tau is not required for cell death in this model. Moreover,
hyperphosphorylation of Tau at serine 262 following PP2A inhibition does not require DLK.
Hence, loss of PP2A function triggers two independent neuropathologies: 1) Tau
hyperphosphorylation and 2) DLK activation and subsequent neuronal cell death. These findings
suggest that combination therapies targeting both Tau and DLK may be useful in
neurodegenerative diseases with impaired PP2A function.

2.2 Significance Statement
Protein phosphatase 2A (PP2A) is a major cellular phosphatase required for neuronal
survival and dephosphorylation of Tau and whose activity is decreased in Alzheimer’s disease.
Here we demonstrate that PP2A plays an evolutionarily conserved role in flies and mice, inhibiting
activation of MAP3K12, DLK, an important neuronal stress kinase. Inhibition of PP2A results in
DLK-dependent synaptic terminal overgrowth at the Drosophila neuromuscular junction and
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neuronal cell death in mammalian cortical neurons. Surprisingly, PP2A-dependent activation of
DLK signaling and neuronal cell death are independent of Tau, demonstrating that Tau
hyperphosphorylation and DLK apoptotic signaling are parallel pathways downstream of PP2A
dysfunction. These findings identify the DLK stress kinase pathway as an important PP2A target
in neuronal health and disease.

2.3 Introduction
Alzheimer’s disease (AD) is the most common form of dementia and is characterized by
the accumulation of toxic protein species, including hyperphosphorylated Tau (Grundke-Iqbal et
al., 1986). Protein Phosphatase 2A (PP2A) plays a central role in the dephosphorylation of Tau,
and PP2A activity is markedly decreased in AD brains, likely contributing to the accumulation of
hyperphosphorylated Tau (Gong et al., 1993; Liu et al., 2005; Sontag et al., 1996; Sontag and
Sontag, 2014). Inhibiting PP2A in neurons promotes cell death both in vitro and in vivo, so the
AD-associated decrease in PP2A activity may contribute to neuronal loss (Arendt et al., 1998;
Kamat et al., 2013; Sun et al., 2003). Previous studies proposed that the neuronal cell death induced
by PP2A inhibition is most likely linked to the alteration of Tau phosphorylation status (Gong et
al., 2000a; Kins et al., 2001; Taleski and Sontag, 2018). Here, we present evidence for an
alternative model wherein the DLK (dual leucine zipper kinase, a.k.a. MAP3K12) stress kinase
signaling cascade is activated downstream of decreased PP2A function to promote neuronal
apoptosis in a Tau-independent manner.
We previously identified a role for PP2A in Drosophila synaptic development,
demonstrating that PP2A acts antagonistically to glycogen synthases kinase 3β (GSK-3β, Shaggy
in flies) to modulate arborization of the neuromuscular junction (NMJ). At the time, we
hypothesized that the phosphatase/kinase pair affected synaptic development through
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dysregulation of the cytoskeleton (Viquez et al., 2009). Later, we discovered that cytoskeletal
dysregulation activates DLK in mammals and its ortholog Wallenda (Wnd) in Drosophila (Valakh
et al., 2013, 2015a). In flies, elevated Wnd signaling stimulates a transcriptional program that
induces increased synaptic arborization at the Drosophila NMJ, a similar phenotype to that
observed in flies with decreased PP2A activity (Collins et al., 2006). In mammals, increased DLK
signaling triggers a transcriptional program that promotes axon regeneration in the peripheral
nervous system but that can induce apoptosis in CNS neurons (Asghari Adib et al., 2018; Xiong
et al., 2010a). Importantly, DLK signaling is increased in the brains of AD model mice and likely
in AD patients, and inhibition of DLK extends lifespan and improves behavioral outcomes in
mouse models of familial AD (Le Pichon et al., 2017). This confluence of findings led us to revisit
our prior studies of PP2A, and to explore the hypothesis that PP2A inhibition may function through
the DLK/Wnd pathway in both Drosophila and mammalian neurons.
Here we demonstrate that loss of neuronal PP2A activity activates Wnd/DLK signaling in
both Drosophila motor neurons and cultured mammalian cortical neurons. In the fly, increased
Wnd signaling leads to activation of a transcriptional stress response program and resulting
changes in synaptic morphology. Pharmacological inhibition of PP2A in mouse cortical neurons
leads to DLK-dependent apoptosis. Surprisingly, loss of PP2A activity in Tau knockout neurons
still activates DLK and induces apoptosis, demonstrating that the accumulation of
hyperphosphorylated Tau and the activation of DLK apoptotic signaling are parallel pathways
downstream of PP2A dysfunction. Hence, this study identifies PP2A as an evolutionarily
conserved inhibitor of DLK stress kinase signaling, with potential roles in regulating both
development and disease.
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2.4 Results
2.4.1 PP2A inhibits DLK signaling to restrain synaptic terminal growth at the
Drosophila NMJ
Neuronal PP2A function is required for restraining growth of the synaptic terminal at the
Drosophila neuromuscular junction (NMJ) during development (Viquez et al., 2009, 2006),
however the molecular mechanisms linking PP2A activity to proper synaptic development are
unknown. We previously inhibited PP2A via neuronal expression of a dominant negative transgene
(Viquez et al., 2009, 2006). We confirmed this result, through expression of the dominant negative
(PP2A-DN) and independently verified PP2A’s role at the NMJ through expression of an RNAi
transgene targeting the PP2A catalytic subunit, Microtubule Stars, (PP2A-C RNAi). Third instar
larvae expressing either of these two transgenes under the control of motoneuron-specific DVGlutGal4 were dissected and stained for the pre-synaptic marker Drosophila Vesicular Glutamate
Transporter (DVGlut) to identify synaptic boutons. Each of these manipulations leads to synaptic
overgrowth, as quantified by an increase in the number of synaptic boutons on the type 1b muscle
4 NMJ compared to animals expressing a control transgene. While both methods to inhibit PP2A
lead to synaptic terminal overgrowth, expression of PP2A-C RNAi also led to a decrease in signal
while staining for synaptic antigens (Fig. 1 A and B). Neuronal expression of either of two separate
RNAis against the related protein phosphatase PP5 induced no change in the number of synaptic
boutons compared to expression of a control RNAi, demonstrating selectivity of the PP2A
phenotype (Fig. 1 A and B). Having confirmed and extended our prior studies demonstrating that
PP2A inhibition induces synaptic terminal overgrowth, we next tested the hypothesis that
Wnd/DLK signaling functions downstream of PP2A to drive the increase in synaptic bouton
number.
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To investigate the role of Wnd/DLK signaling in the PP2A-dependent synaptic terminal
overgrowth phenotype, we co-expressed a validated Wnd RNAi (Valakh et al., 2013) along with
the dominant negative or an RNAi targeting the catalytic subunit of PP2A in motoneurons.
Inhibition of Wnd/DLK leads to a significant reduction in the number of synaptic boutons at the
NMJ, suppressing the synaptic bouton number to wildtype levels (Fig. 1 C and D). Expression of
Wnd RNAi in a wildtype background does not affect bouton number (Fig. 1 C and D), consistent
with the hypothesis that Wnd/DLK signaling is regulated by PP2A function. As an independent
method of suppressing Wnd, we used an inhibitor of the mammalian ortholog DLK, GNE-3511,
that we previously validated inhibits Drosophila Wnd (Russo and DiAntonio, 2019).
Pharmacological inhibition of Wnd significantly reduced the number of boutons in animals
expressing either a dominant negative PP2A or an RNAi against the catalytic subunit (Fig. 1 E and
F). Hence, genetic and pharmacological studies demonstrate that Wnd signaling is required for the
synaptic terminal overgrowth induced by impaired neuronal PP2A activity.

2.4.2 A DLK-regulated transcriptional program is activated by loss of PP2A
function
In our original study demonstrating that decreased neuronal PP2A activity induces synaptic
terminal overgrowth we hypothesized that this was due to local signaling converging on the
cytoskeleton (Viquez et al., 2009). However, the known role of Wnd/DLK in regulating a
transcriptional program to control synaptic terminal growth (Collins et al., 2006) inspired us to test
whether there were transcriptional changes in neurons with reduced PP2A activity. We first tested
whether inhibition of PP2A causes transcriptional changes in a well-known DLK-dependent
cellular stress response program. To do this we employed a Puckered LacZ enhancer trap
(PucLacZ). Expression of Puckered, a phosphatase which targets JNK, is positively regulated by
JNK activity. Thus, increased Wnd signaling results in elevated levels of Puckered transcription
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and higher intensity of LacZ staining (Martín-Blanco et al., 1998; Xiong et al., 2010a). Expressing
either dominant negative PP2A or RNAi targeting PP2A-C in neurons triggers a substantial
increase in Puckered expression. Expression of RNAi lines targeting the related protein
phosphatase PP5 did not significantly alter levels of Puckered expression (Fig. 2 A and B). These
data demonstrate that loss of PP2A activity alters transcription in neurons and with our previous
findings lead us to hypothesize that this transcriptional change was Wnd-dependent. Co-expression
of Wnd RNAi with either dominant negative PP2A or PP2A-C RNAi lowered PucLacZ induction
back to wildtype levels (Fig. 2 C and D). Therefore, we conclude that loss of neuronal PP2A
activity results in the induction of a Wnd-dependent transcriptional response.
We hypothesized that this Wnd-dependent transcriptional program is required for the
synaptic overgrowth induced by loss of PP2A activity. Previously, we demonstrated that the
transcription factor Fos is required for Wnd-dependent transcriptional changes and synaptic
terminal overgrowth (Collins et al., 2006). Hence, we expressed a dominant negative Fos transgene
in neurons and found it blocks the increase in number of synaptic boutons induced by PP2A
inhibition (Fig. 2 E and F). Therefore, we conclude that loss of neuronal PP2A activity induces
synaptic terminal overgrowth by activating a Wnd- and Fos-dependent transcriptional program.

2.4.3 GSK-3β antagonizes PP2A upstream of DLK activation
GSK-3β is a kinase that often functions antagonistically with the phosphatase PP2A,
including in the regulation of synaptic terminal growth in Drosophila (Janssens and Goris, 2001;
Viquez et al., 2009). Indeed, co-expression of a dominant negative form of GSK-3β suppresses
both the increase in the number of synaptic boutons and the induction of the PucLacZ upon
neuronal inhibition of PP2A (Fig. 3 A-D) (Viquez et al., 2009). Previously we postulated that
PP2A and GSK-3β act antagonistically at the level of a target substrate to modulate microtubule
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associated proteins and thus cytoskeletal structure (Viquez et al., 2009). However, we showed
above that the synaptic overgrowth phenotype requires a Wnd-dependent transcriptional program.
These data present the possibility of an alternative model to that which we originally proposed,
wherein GSK-3β may act downstream of increased Wnd signaling to effect phenotypic changes in
animals with reduced neuronal PP2A activity.
In order to test whether GSK-3β can act downstream of Wnd/DLK activity, we used
highwire (hiw) mutants, an independent genotype that activates Wnd/DLK signaling and drives
synaptic terminal growth (Collins et al., 2006). Hiw is an E3 ubiquitin ligase that targets Wnd for
degradation, hence in hiw mutants Wnd is upregulated and activated (Collins et al., 2006). If GSK3β acts downstream of Wnd, then we would expect a loss of GSK-3β activity to suppress Wnddependent transcriptional changes and synaptic terminal overgrowth in hiw mutants. As previously
demonstrated, expression of both Wnd RNAi and the Fos dominant negative transgene suppress
synaptic terminal overgrowth from loss of Hiw (Collins et al., 2006). In contrast, expression of the
dominant negative GSK-3β that potently suppresses the PP2A phenotype fails to suppress the
increase in synaptic bouton number when hiw is disrupted (Fig. 3 E and F). These data are not
consistent with GSK-3β acting downstream of Wnd signaling, and instead support a model in
which GSK-3β and PP2A antagonistically regulate a protein or process that is necessary to inhibit
Wnd/DLK signaling.

2.4.4 PP2A inhibition in mammalian cortical neurons induces DLK-dependent
cell death
Loss of PP2A activity is observed in Alzheimer’s disease patients and is thought to
contribute to disease progression via an undefined mechanism (Shentu et al., 2018; Sontag et al.,
2004; Vogelsberg-Ragaglia et al., 2001a). One proposed mechanism is the formation of toxic
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species of hyperphosphorylated Tau, a well-studied substrate of PP2A (Gong et al., 1993; Liu et
al., 2005; Sontag et al., 1996). Inhibition of PP2A activity, either through genetic manipulations
or pharmaceutical methods, in mammalian cortical neurons in vitro leads to neuronal cell death
(Kim et al., 1999a; Kins et al., 2001). Wnd and DLK function are conserved between flies and
mice in the axon regeneration pathway (Shin et al., 2012b; Xiong et al., 2010a). Here we
investigate the hypothesis that PP2A-dependent inhibition of DLK signaling is also evolutionarily
conserved, and that DLK may trigger neuronal cell death upon loss of PP2A function in
mammalian cortical neurons.
We first asked whether PP2A inhibition in cultured mouse cortical neurons activates DLK
signaling. To assess DLK signaling, we assayed phosphorylation of the direct DLK substrate
MKK4, a MAP double kinase. Primary mouse cortical neurons were cultured from E16-18
embryos for 12 days before treatment for 4 hours with either vehicle or the selective PP2A
inhibitor, LB-100. LB-100 treatment led to significantly higher levels of phosphorylated MKK4
compared to those treated with a DMSO control. To test whether phosphorylation of MKK4 is
DLK-dependent, neurons were pre-treated with either DLK inhibitor GNE-3511 or DMSO 30
minutes before LB-100 application. Pre-treatment with DLK inhibitor blocks the increase in
pMKK4 (Fig. 4 A and B). Hence, PP2A inhibition in mammalian cortical neurons activates DLK
signaling.
We next investigated whether DLK signaling promotes neuronal cell death upon PP2A
inhibition. DLK signaling is pro-apoptotic in other contexts (Chen et al., 2008; Fernandes et al.,
2014; Ghosh et al., 2011; Pozniak et al., 2013a; Watkins et al., 2013; Welsbie et al., 2013), and so
we first tested whether the cell death caused by PP2A inhibition is apoptotic. Primary cortical
neurons were treated with LB-100 and cell death/viability was assessed every 24 hours for three
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days. To block apoptosis, we infected cortical neurons with lentivirus expressing the anti-apoptotic
protein BCL-XL or a control GFP construct at DIV 3. Cortical neurons were treated on DIV 9 with
either LB-100 or DMSO and cell viability was measured using an MTT survival assay. BCL-XLexpressing cells were significantly protected at all timepoints compared to GFP-expressing
controls. Next, we tested whether the cell death caused by PP2A inhibition was DLK-dependent.
Cells were treated with DLK inhibitor or DMSO 30 minutes prior to LB-100 treatment and the
relative cell death was measured as described above. DLK inhibitor pre-treatment phenocopied
BCL-XL expression, potently protecting neurons treated with LB-100 out to 72 hours after
treatment (Fig. 4C). These findings demonstrate that PP2A inhibition in cultured cortical neurons
leads to a cell death that is both apoptotic and DLK-dependent.

2.4.5 PP2A inhibition Triggers DLK-dependent Neuronal Cell Death
Independent of Tau
The microtubule-associated protein Tau is a well-defined target of PP2A. Loss of PP2A
activity leads to an alteration in the phosphorylation pattern of Tau, which can form a toxic protein
species that is a hallmark of Alzheimer’s disease and tauopathies. We investigated whether
hyperphosphorylated Tau participates in DLK-dependent cell death following PP2A inhibition.
We first asked whether DLK signaling influences Tau phosphorylation at serine 262, a known
target of PP2A and a site of increased phosphorylation in neurodegenerative diseases (Keramidis
et al., 2020; Liu et al., 2005; Qian et al., 2010). Primary mouse cortical neurons expressed either
BCL-XL or a GFP control or were treated with either DMSO or DLK inhibitor 30 minutes prior
to treatment with LB-100. Following 4 hours of LB-100 treatment, protein was collected and levels
of Tau phosphorylated at serine 262 (pTau) was measured by Western blot. PP2A inhibition led
to the expected dramatic increase in pTau, and neither BCL-XL expression nor DLK inhibition
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blocked this effect (Fig. 5 A and B). Hence, levels of Tau phosphorylated at serine 262 are not
changed by conditions that block neuronal cell death following PP2A inhibition.
Having demonstrated that DLK signaling is not required for increased phosphorylation of
Tau at serine 262, we next asked the converse question—is hyperphosphorylated Tau necessary to
activate DLK signaling following PP2A inhibition? This is an attractive hypothesis because we
previously demonstrated that disrupting the mammalian cytoskeleton can activate neuronal DLK
signaling (Valakh et al., 2013, 2015a), and a dysregulated cytoskeleton is observed in cases of
increased Tau phosphorylation (Merrick et al., 1997; Sontag et al., 1999). We cultured neurons
from Tau knock out mice, treated them with LB-100, and assessed DLK activation by measuring
levels of phosphorylated MKK4. Results from Tau knockout and wildtype neurons were very
similar, showing an increase in pMKK4 four hours after treatment with LB-100 (Fig. 5 C and D).
These results demonstrate that hyperphosphorylated Tau is not required for the activation of DLK
signaling following PP2A inhibition.
The findings above lead us to hypothesize that cell death triggered by PP2A inhibition is
DLK-dependent and Tau-independent. To test this, we treated neurons cultured from Tau KO mice
with LB-100 and measured cell death, predicting that the neurons would die even in the absence
of hyperphosphorylated Tau. Tau KO neurons showed significant cell death 72 hours after LB100 treatment, phenocopying results observed in wildtype neurons and demonstrating that Tau is
not necessary for PP2A inhibition to trigger cell death (Fig. 5 E and F). Hence, PP2A inhibition
activates

two

independent

pro-degenerative

pathways,

DLK

activation

and

Tau

hyperphosphorylation. Targeting both DLK and Tau may offer benefits for the treatment of
Alzheimer’s disease and other disorders with prominent PP2A dysfunction.
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2.5 Discussion
Here we demonstrate that PP2A acts to inhibit DLK signaling in neurons. Our study, in
conjunction with prior work, supports a model wherein PP2A inhibition alters the cytoskeleton
which triggers an increase in DLK signaling. Activated DLK induces a transcriptional stress
response that alters synaptic development at the Drosophila NMJ and promotes cell death in
mammalian cortical neurons. Moreover, we show that PP2A-dependent inhibition of DLKinduced neuronal cell death and Tau hyperphosphorylation are independent. These findings
identify a mechanistic link between PP2A inhibition and DLK activation with implications for the
pathogenesis of neurodegenerative diseases.

2.5.1 PP2A and DLK/Wallenda signaling
PP2A and GSK-3β function antagonistically in neurons to regulate the status of a family
of substrates including many microtubule-associated proteins, ultimately affecting the
organization of the cytoskeleton (Janssens and Goris, 2001). Our previous studies demonstrated
that this pair acts to control synaptic terminal morphology at the Drosophila NMJ, and we assumed
at the time this was due to local disruption of the cytoskeleton (Viquez et al., 2009). However, here
we have shown that PP2A and GSK-3β collaborate to inhibit the activation of a downstream MAP
kinase signaling cascade headed by the MAP triple kinase DLK/Wallenda. DLK is a major
neuronal stress kinase that is activated by cytoskeletal disruption in both Drosophila and mammals
(Asghari Adib et al., 2018; Valakh et al., 2013, 2015a), suggesting that DLK acts as a sensor and/or
effector downstream of cytoskeletal perturbations in neurites. While Wnd/DLK can function
locally at the NMJ (Klinedinst et al., 2013), in cases of injury, the DLK/JNK signaling module is
transported retrogradely to the nucleus, where it activates a transcriptional response to mount a
cellular response to the stress (Shin et al., 2012b; Xiong et al., 2010a). DLK signaling activates
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disparate responses depending on the context of activation, such as neuronal subtype, including a
regenerative process that triggers increased growth at the Drosophila NMJ and the injured
mammalian PNS (Hammarlund et al., 2009b; Shin et al., 2012a; Xiong et al., 2010a; Yan et al.,
2009), but induces a pro-apoptotic signal in mammalian retinal ganglion cells and cortical neurons
(Chen et al., 2008; Pozniak et al., 2013a; Watkins et al., 2013; Welsbie et al., 2013). Here, we
propose a model to tie these findings together, suggesting that PP2A acts to maintain cytoskeletal
homeostasis that in turn keeps DLK signaling at a low basal state. When PP2A activity is disrupted,
the cytoskeleton is perturbed and DLK is activated, triggering the stress response appropriate for
that cell, including death of cortical neurons. Hence, a subset of the deleterious outcomes attributed
to inhibition of neuronal PP2A is due to the secondary activation of DLK.

2.5.2 PP2A signaling, Tau, and the mechanism of neuronal cell death
PP2A inhibition causes cell death both in vitro and in vivo indicating that PP2A function
is essential for neuron survival in the central nervous system (Kamat et al., 2013; Kim et al., 1999b;
Kins et al., 2001). Loss of PP2A function is observed in Alzheimer’s disease patient brains, due to
lowered mRNA levels of the PP2A catalytic subunit, increased expression of the inhibitor protein
cancerous inhibitor of PP2A (CIP2A), and changes in expression of methyltransferases that
regulate PP2A activity (Gong et al., 1993, 1995; Liu et al., 2005; Park et al., 2018; Shentu et al.,
2018; Sontag et al., 2004; Vogelsberg-Ragaglia et al., 2001a). Taken together, the strong evidence
that PP2A activity is lowered in patient brains has motivated mechanistic studies of the role of
PP2A in neuronal survival. One of the best studied targets of PP2A in the nervous system is Tau,
which forms toxic species when hyperphosphorylated that are present not only in Alzheimer’s
disease patient brains but also in tauopathies (Gong et al., 1995; Liu et al., 2005; Merrick et al.,
1997; Sontag et al., 1999, 1996; Sontag and Sontag, 2014). The dual role of PP2A in suppressing
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Tau hyperphosphorylation and neuronal cell death has led to the hypothesis that this neuronal cell
death is due to the effects of hyperphosphorylated Tau (Iqbal et al., 2009; Taleski and Sontag,
2018). Here we test this model directly by assessing the impact of PP2A inhibition in the absence
of Tau and explore alternate mechanisms for this neuronal cell death.
We find that PP2A inhibition activates a DLK signaling cascade that promotes cortical
neuron cell death. The MAP triple kinase DLK is a major neuronal stress kinase, sensing cellular
stress and launching a transcriptional program in response (Asghari Adib et al., 2018; Valakh et
al., 2015a; Xiong et al., 2010a). Increased DLK signaling is implicated in neurodegenerative
diseases—signaling is elevated in murine models of Alzheimer’s disease and amyotrophic lateral
sclerosis (ALS) and DLK inhibition improved neuronal survival and behavioral phenotypes in
these models. Moreover, increased levels of a key target of DLK signaling, the phosphorylated
form of the transcription factor Jun, is observed in post-mortem nervous tissue of Alzheimer’s and
ALS disease patients (Le Pichon et al., 2017). Together, our findings and published work support
the hypothesis that inappropriate activation of DLK is common to multiple neurodegenerative
diseases, and that dampening this stress pathway has potential as a treatment.
Finally, we explored potential mechanistic links between the Tau hyperphosphorylation
and increased DLK signaling that occur as a consequence of PP2A inhibition. Surprisingly, we
find that when PP2A is inhibited, hyperphosphorylation of Tau is not required for either DLK
activation or neuronal death. This exciting result extends our understanding of neurodegenerative
mechanisms downstream of PP2A inhibition. In patients, we expect that both hyperphosphorylated
Tau and activated DLK will contribute to neuropathology, suggesting that therapies targeting both
Tau and DLK may provide benefits for the treatment of these devastating neurodegenerative
diseases.
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2.6 Material and Methods
Fly Stocks and Husbandry. Drosophila were maintained using standard techniques and raised at
25°C and 60% relative humidity. The following stocks were used in this study: HiwND9 (Wan et
al., 2000), DVGlut-gal4 (Daniels et al., 2008), UAS-PP2A-DN, a dominant negative form of PP2A
catalytic subunit microtubule stars obtained from Suzanne Eaton (Hannus et al., 2002), Wallenda
RNAi (Vienna stock center, #103410), PucLacZE69(Martín-Blanco et al., 1998), elav-gal4 (Yao
and White, 1994). Fly stocks obtained from the Bloomington Stock Center included: UAS-PP2AC RNAi, an RNAi targeting the catalytic subunit of PP2A microtubule stars (#27723), UASsggA81T, a dominant negative form of the Drosophila ortholog of GSK-3β (#5359), UAS-LexA
RNAi (#67947), UAS-PP5 RNAi (#42794 and #57307), UAS-Fos-DN (#7214). Gal4 drivers were
crossed to UAS-LexA RNAi as a control for expression of experimental constructs. Roughly equal
numbers of male and female flies were tested, with the exception of Hiw mutants and crosses using
the DVGlut-gal4 driver, in which cases only males were examined. Flies raised on DLK inhibitor
were crossed in vials with 35 µM GNE-3511 (MedChem Express HY-12947) or an equivalent
volume of DMSO in Instant Drosophila Blue Food Medium (Carolina, #173210) (Russo and
DiAntonio, 2019).
Immunohistochemistry. Wandering third instar larvae were dissected in cold PBS and fixed in
either bouin’s fixative for 10 minutes (DVGlut, HRP) or 4% PFA in PBS for 20 minutes (Elav,
beta-galactosidase). After fixing, larvae were washed in PBS + 0.1% Triton X-100 (PBS-T)
followed by blocking in 5% normal goat serum in PBS-T for at least 30 minutes. All antibodies
were incubated in 5% normal goat serum blocking solution. The following antibodies were used:
rabbit anti-DVGlut (1:5,000 (Daniels et al., 2004)), rat anti-Elav (1:50, Developmental Studies
Hybridoma Bank AB_528218), mouse anti-beta-galactosidase (1:100, Developmental Studies
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Hybridoma Bank AB_2314509). The following secondary antibodies were used at 1:1000 for 90
minutes: cy3-conjugated goat anti-HRP (Jackson ImmunoResearch, Cat# 123-165-021;
AB_2338959), AlexaFluor 488 goat anti-rabbit (ThermoScientific – Invitrogen, Cat# A-11034;
AB_2576217),

cy3

goat

anti-mouse

(Jackson

ImmunoResearch,

Cat#

115-165-146;

AB_2338680), and AlexaFluor 488 chicken anti-rat (ThermoScientific – Invitrogen Cat# A21470; AB_2535873). After secondary staining, larval preps were stored in 70% glycerol in PBS
until being mounted in vectashield (Vector Laboratories).
Imaging and Image Analysis in Drosophila. Synaptic growth was assessed using larval preps
stained for DVGlut and HRP which were imaged using the 40X objective on a Leica TCS SPE
confocal microscope. Images shown were all taken at the same gain, adjusted to be as bright as
possible without oversaturation, and with identical z-stack step sizes. Bouton number was
quantified as previously described (Collins et al., 2006). DVGlut-positive boutons were manually
counted on muscle 4 of larval segments A2-A4. PucLacZ measurements were taken by staining
larval ventral nerve cords and taking images with a Leica TCS SPE confocal microscope using the
20X objective. Average PucLacZ intensity was quantified in the neuronal nuclei along the dorsal
midline of the ventral nerve cord as described previously (Xiong et al., 2010a). Briefly, neurons in
the z-stack images are identified using an Elav stain and the average intensity of beta-galactosidase
is measured in the defined area. All images were taken at the same gain and with the same z-step
size for all conditions in each experiment.
Primary Cortical Neuron Culture. Primary neurons were cultured from E16.5-E18.5 mouse
embryos. For Fig.ure 4 CD1 mice were used, and for Fig.ure 5 C57BL/6 mice (Charles River
Laboratories) were used as wildtype controls for Tau KO mice obtained from John Cirrito
(Washington University in St. Louis). Cortices were dissected in ice cold Hank’s Buffered Salt
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Solution and digested in Accumax (StemCell Technologies, cat# 07921) for 25 minutes. Digested
cells were then rinsed once in neurobasal media with 10% fetal bovine serum, followed by
trituration of the cell pellet in this media and plating at 250,000 cells per mL. Four hours after
plating, media was changed to maintenance media of neurobasal media with 1:50 B-27 supplement
(Thermo Fischer Scientific, cat# 17504044). Half of media was changed every 3 days and included
a 1:200 addition of FDU to prevent growth of non-neuronal cells. On DIV 3 lentivirus was added,
either a GFP control or a BCL-XL construct. Cells were treated with 1 µM LB-100 on DIV 9 or
an equivalent volume of DMSO then treated 24 hours later for cell survival studies or collected 4
hours later for Western blotting assays. Cells treated with DLK inhibitor were treated 30 minutes
prior to LB-100 treatment with 500 nM GNE-3511 (MedChem Express HY-12947) or an
equivalent volume of DMSO.
Western Blots. To analyze phosphorylation evens on Tau and MKK4 following LB-100 treatment
protein was collected and analyzed by Western blot from DIV 10 primary cortical neurons. Protein
was collected in RIPA buffer with protease inhibitor (Millipore Sigma, cat# 11873580001) and
phosphatase inhibitor (Sigma-Aldrich, cat# P0044) after washing cells in ice cold PBS. Cells were
spun down for 4 minutes at 4,000 RCF, then protein was mixed with Laemmli buffer and 2mercaptoethanol (Sigma-Aldrich, cat# M3148) and boiled at 100°C for 10 minutes. Samples were
run on 4-20% Mini-PROTEAN® TGX Precast Protein Gels (Bio-Rad Laboratories, cat# 4561093)
in duplicate, with one gel being reserved for the phosphorylated form of the protein and the other
for the non-phosphorylated control. Gels were transferred to nitrocellulose membranes using
Trans-Blot® Turbo Midi Nitrocellulose Transfer Packs (Bio-Rad Laboratories, cat# 1704159).
Membranes were blocked in 5% bovine serum albumin (Sigma-Aldrich, cat# A3912-50G) in
TBS+0.1% tween for 60 minutes. Membranes were then incubated in one of the following
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antibodies overnight: 1:1,000 rabbit anti-MKK4 (Cell Signaling Technologies, cat# 9152), 1:1,000
rabbit anti-phospho-MKK4 (ser257/thr261) (Cell Signaling Technologies, cat# 9156), 1:500
mouse anti-Tau-5 (Thermo Fischer Scientific, cat# MA512808), 1:200 rabbit anti-phospho-Tau
(ser262) (Thermo Fischer Scientific, cat# 44750G), 1:5,000 rabbit anti-HSP90 (Cell Signaling
Technologies, cat# 4877S). Membranes were then incubated in the following secondary antibodies
in PBST + 5% BSA for 60 minutes: Peroxidase AffiniPure Goat Anti-Rabbit IgG (Jackson
ImmunoResearch Laboratories cat# 111-035-045) at 1:5,000 for MKK4, pMKK4, and Tau-5 blots
and 1:10,000 for HSP90 blots, Peroxidase AffiniPure Goat Anti-Mouse IgG (Jackson
ImmunoResearch Laboratories, cat# 115-035-003) at 1:5,000. Western blots were developed with
Immobilon Western Chemiluminescent Substrate (EMD Millipore) and imaged on a G:Box
Chemi-XX6 (Syngene). Blots were quantified using ImageJ (NIH, v1.53c), with phosphorylated
forms of proteins being normalized to the non-phosphorylated forms.
MTT Assay. Cortical neurons were cultured as described above in 96 well plates. On DIV 9, 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Thermo Fischer Scientific,
cat# M6494) was dissolved in sterile PBS at 5mg/mL. An appropriate volume was added to media
such that changing half of the media in the 96 well plate resulted in a final concentration of
0.5mg/mL. Cells were incubated with MTT for 4 hours then lysed by replacing media with DMSO
(50 µL per well). The active cells converted MTT into formazan, resulting in a purple solution the
intensity of which was measured using the absorbance setting on a POLARstar OPTIMA plate
reader (BMG LabTech). Background was subtracted from all cells based on the average reading
of 8 wells without cells. Percent of cell death was calculated by comparing individual well readings
to the average intensity of untreated wells on the same plate.
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Experimental Design and Statistical Analyses. For quantification of synaptic boutons at the
neuromuscular junction at least 3 larvae were quantified for each genotype with each NMJ being
an N of 1, as each motor neuron targets a single muscle 4 hemi-segment. For the quantification of
PucLacZ intensity in the ventral nerve cord at least 2 larvae were used per genotype, with each
larva representing an N of 1. Experimental genotypes were compared to control genotypes on the
same slide and from the same dissection, with all measurements being performed blinded to the
genotype. Western blot experiments were run at least 3 times with each experiment being a
separate biological replicate, ie: collected neurons were from different mice. Protein collected was
pooled from 2-3 technical replicates (wells on the same plate). MTT assays were repeated with at
least 3 biological replicates and at least 4 technical replicates (wells on the same plate).
All data is represented as mean ± SEM with exact values represented as individual data points
where possible. Statistical tests are described below each Fig.ure, including p-value. GraphPad
Prism 9 was used to perform all statistical tests.
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2.8 Figures

Figure 1. PP2A inhibits DLK signaling to restrain synaptic terminal growth at the Drosophila NMJ
(A) Representative images of synaptic terminal overgrowth at the NMJ of third instar larvae. Transgenes
are being driven by DVGlutgal4 in the presence of UAS-Dcr to improve RNAi knockdown. Tissue is
stained for the presynaptic marker DVGlut (green) and the nerve membrane with anti-HRP (red). Scale bar
is 25 µM. (B) Quantification of the mean (± SEM) number of boutons on the type 1b synapse on muscle 4.
Expression of PP2A-DN or PP2A-C RNAi significantly increases the number of boutons compared to an
animal expressing a control RNAi (p < 0.0001) as measured by a one-way ANOVA with Tukey’s multiple
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comparison test. Expression of either of two RNAis against PP5 is not significantly different from animals
expressing a control RNAi (p = 0.8450 and p = 0.9991 respectively). (C) Representative images of the
suppression of synaptic terminal overgrowth from PP2A inhibition by Wnd RNAi in third instar larvae.
Transgenes are being driven by DVGlutgal4 in the presence of UAS-Dcr to improve RNAi knockdown.
Tissue is stained for the presynaptic marker DVGlut (green) and the nerve membrane with anti-HRP (red).
Scale bar is 25 µM. (D) Quantification of the mean (± SEM) number of boutons in larvae driving constructs
using DVGlutgal4 and UAS-Dcr. Co-expression of Wnd RNAi compared to co-expression a LexA RNAi
control with PP2A inhibition significantly suppresses an increase in synaptic bouton number (p < 0.0001
for PP2A-DN and p = 0.0004 for PP2A-C RNAi). Statistical significance was measured by a one-way
ANOVA with Tukey’s multiple comparison test. (E) Representative images of the suppression of synaptic
terminal overgrowth in third instar larvae from PP2A inhibition by DLK inhibitor (GNE-3511, 35 µM).
Transgenes are being driven by DVGlutgal4 in the presence of UAS-Dcr to improve RNAi knockdown.
Tissue is stained for the presynaptic marker DVGlut (green) and the nerve membrane with anti-HRP (red).
Scale bar is 25 µM. (F) Quantification of the mean (± SEM) number of boutons in larvae fed either DMSO
or DLK inhibitor (GNE-3511, 35 µM). Being raised on DLKi as compared to DMSO significantly
suppressed synaptic overgrowth in larvae expressing Hiw RNAi (p < 0.0001), PP2A-DN (p <0.0001), or
PP2A-C RNAi (p =0.0003) under a DVGlutgal4 with UAS-Dcr. Statistical analysis was done using
unpaired T-tests with Welch correction.
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Figure 2. A DLK-regulated transcriptional program is activated by loss of PP2A function
(A) Representative images of ventral nerve cords in larvae expressing neuronal transgenes to inhibit
neuronal PP2A or PP5. The neuronal protein Elav is stained in green and LacZ from the PucLacZ
enhancer trap is stained in red. Transgenes are expressed using the pan-neuronal driver ElavGal4 along
with UAS-Dcr to improve RNAi knock down. Scale bars are 50 µM. (B) Quantification of the mean (±
SEM) PucLacZ fold induction in neurons of the ventral nerve cord. Expression of PP2A-DN or PP2A-C
RNAi (p <0.0001 for both) significantly increases PucLacZ induction compared to expression of a control
LexA RNAi, but PP5 RNAi expression has no significant effect (p =0.8506 for PP5 RNAi #1 and p
=0.395 for PP5 RNAi #2) from a one-way ANOVA analysis with Tukey’s multiple comparison test. (C)
Representative images of the ventral nerve cords in larvae expressing transgenes under the neuronal
driver ElavGal4. The neuronal protein Elav is stained in green and LacZ from the PucLacZ enhancer trap
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is stained in red. Transgenes are expressed using the pan-neuronal driver ElavGal4 along with UAS-Dcr
to improve RNAi knock down. Scale bars are 50 µM. (D) Quantification of the mean (± SEM) PucLacZ
fold induction in neurons of the ventral nerve cord. Expression of Wnd RNAi with PP2A-DN (p =0.0002)
or PP2A-C RNAi (p =0.0002) significantly suppresses PucLacZ induction compared to co-expression
with a control LexA RNAi. Statistical significance was measured by one-way ANOVA with Tukey’s
multiple comparison test. (E) Representative images of neuromuscular junctions on muscle 4 of third
instar larvae. Tissue is stained for presynaptic marker DVGlut (green) and neuronal membrane marker
HRP (red). Expression of transgenes is driven by the glutamatergic neuron driver DVGlutgal4 in the
presence of UAS-Dcr to improve RNAi processing. Scale bars are 25 µM. (F) Quantification of the mean
(± SEM) number of boutons on muscle 4. Driving Fos-DN suppresses an increase in synaptic bouton
number when co-expressed with PP2A-DN or PP2A-C RNAi compared to co-expression of a control
LexA RNAi (p <0.0001 for both forms of PP2A inhibition). Statistical significance was measured by oneway ANOVA with Tukey’s multiple comparison test.
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Figure 3. GSK-3β counteracts PP2A upstream of DLK activation
(A) Representative images of neuromuscular junction of muscle 4 of third instar larvae. Larvae are
expressing either PP2A-DN or PP2A-C RNAi under the DVGlutgal4 driver with UAS-Dcr to inhibit
PP2A function along with either a control RNAi against LexA or a GSK-3β-DN transgene. Tissue is
stained for the presynaptic marker DVGlut (green) and the nerve membrane with anti-HRP (red). Scale
bars are 25 µM. (B) Quantification of the mean (± SEM) number of synaptic boutons. Co-expression of
GSK-3β-DN with PP2A-DN or PP2A-C RNAi compared to co-expression of a control LexA RNAi
significantly suppresses the number of synaptic boutons (p <0.0001 for both). Transgenes are driven by
DVGlutgal4 and express UAS-Dcr to improve RNAi knockdown. Statistical analysis comes from a oneway ANOVA with Tukey’s multiple comparison test. (C) Representative images of PucLacZ induction in
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the ventral nerve cord of larvae expressing a control RNAi, PP2A-DN, or PP2A-DN in conjunction with
GSK-3β-DN. The neuronal protein Elav is stained in green and LacZ from the PucLacZ enhancer trap is
stained in red. Transgenes are expressed using the pan-neuronal driver ElavGal4. Scale bars are 50 µM.
(D) Quantification of the mean (± SEM) fold change of PucLacZ induction in neurons of the ventral
nerve cord. Co-expression of GSK-3β-DN with PP2A-DN significantly suppresses the increased PucLacZ
induction (p <0.0001). Transgenes are driven by the neuronal driver ElavGal4 and a one-way ANOVA
with Tukey’s multiple comparison test was performed. (E) Representative images of neuromuscular
junctions on muscle 4 of third instar larvae. Tissue is stained for the presynaptic marker DVGlut (green)
and the nerve membrane with anti-HRP (red). Highwire mutants (HiwND9) express transgenes under the
neuronal driver ElavGal4 with UAS-Dcr to improve RNAi knockdown. Transgenes include a control
RNAi, Wnd RNAi, Fos-DN, and GSK-3β-DN. Scale bars are 25 µM. (F) Quantification of the mean (±
SEM) number of synaptic boutons. Synaptic overgrowth in HiwND9 is suppressed by neuronal expression
of Wnd RNAi or Fos-DN (p <0.0001 for both), but not by expression of GSK-3β-DN (p =0.7608) with
the ElavGal4 driver and UAS-Dcr to improve RNAi knockdown. Statistical analysis was performed with
a one-way ANOVA and Tukey’s multiple comparison test.
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Figure 4. PP2A inhibition in mammalian cortical neurons induces DLK-dependent cell death
(A) Quantification of the mean (± SEM) of pMKK4 in mouse cortical neurons after 4 hours of LB-100
treatment. pMKK4 significantly increases following LB-100 treatment (p =0.0005) while treating the
cells 30 minutes before LB-100 with 500 nM blocks this increase (p =0.9476). Statistical analysis was
performed with a ratio paired T-test.
(B) Representative western blots stained for pMKK4 (serine 257/threonine 261) and HSP90 on one blot
and MKK4 and HSP90 on a second blot. Primary mouse cortical neurons were treated with 1 µM LB-100
on DIV 12 after being pre-treated by 30 minutes with either DMSO or 500 nM DLKi.
(C) Quantification of the mean (± SEM) relative amount of living cells as measured by MTT assay.
Biological replicates were normalized to the level of living cells after 0 hours of 1 µM LB-100 treatment
for 24 hours, 48 hours, and 72 hours following treatment. Cells were expressing a GFP control or the antiapoptotic protein BCLXL or were pre-treated for 30 minutes before LB-100 treatment with either DMSO
or 500 nM DLKi. Each data point represents a biological replicate which is the average of at least 4
technical replicates. There are significantly more living cells in the BCLXL group compared to the GFPexpressing control group at 24, 48, and 72 hours after LB-100 treatment (p =0.000041, p <0.000001, p
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<0.000001 respectively). There are significantly more living cells in the DLKi-treated group compared to
the DMSO-treated group at 24, 48, and 72 hours after LB-100 treatment (p = 0.000054, p <0.000001, p
<0.000001 respectively). There is no significant difference in the percentage of living cells between the
BCLXL-expressing group and the DLKi-treated group at 24, 48, or 72 hours following LB-100 treatment
(p = 0.031533, p = 0.818733, and p = 0.155834 respectively). All statistical tests were unpaired T-tests.
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Figure 5. PP2A inhibition triggers DLK-dependent neuronal cell death independent of Tau
(A) Representative western blots stained with pTau (serine 262), total Tau (Tau-5), and HSP90. Primary
mouse cortical neurons were treated with 1 µM LB-100 for 4 hours. Cells were expressing either a GFP
control or BCLXL or were treated 30 minutes before LB-100 treatment with either DMSO or 500 nM
DLKi. (B) Quantification of the mean (± SEM) fold change in pTau (serine 262) levels following 4 hours
of exposure to 1 µM LB-100 in primary mouse cortical neurons. Cells were expressing a GFP control or
the anti-apoptotic protein BCLXL or were pre-treated 30 minutes before the addition of LB-100 with
DMSO or 500 nM DLKi. There is no significant difference found between any of the treatment groups by
a one-way ANOVA with Tukey’s multiple comparison test. (C) Representative western blots showing
pMKK4 (serine 257/threonine 261), MKK4, and HSP90 levels in primary cortical neurons from wildtype
(C57BL/6) or Tau KO mice treated with 1 µM LB-100 for 4 hours. Cells were pre-treated 30 minutes
before the addition of LB-100 with either DMSO or 500 nM DLKi. (D) Quantification of the mean (±
SEM) fold change in pMKK4 following LB-100 treatment in primary cortical neurons from wildtype
(C57BL/6) and Tau KO mice pre-treated with DMSO or 500 nM DLKi. Both wildtype and Tau KO mice
show a significant increase in pMKK4 following LB-100 treatment (p =0.0010), which is unaffected by
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the presence of Tau (p =0.6242). Statistical significance was measured by two-way ANOVA. (E)
Quantification of mean (± SEM) relative amount of living cells as measured by an MTT assay in primary
cortical neurons from wildtype and Tau KO mice following treatment with 1 µM LB-100 for 0, 24, 48,
and 72 hours. Each data point represents a biological replicate which is the average of at least 4 technical
replicates. There is no significant difference in the percentage of living cells at 24, 48, or 72 hours after
LB-100 treatment between wildtype and Tau KO neurons (p = 0.214032, p = 0.784189, and p = 0.803735
respectively). Statistical significance was measured using unpaired T-tests.
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Chapter 3: Discussion and Future Directions
My work here demonstrates a DLK-dependent program downstream of PP2A inhibition in
vivo in the developing Drosophila peripheral nervous system and in vitro in the mammalian central
nervous system. In the fly nervous system PP2A inhibition had been previously demonstrated to
cause synaptic overgrowth but was hypothesized to be caused by a loss of cytoskeletal support. In
this work, I have instead shown that this altered synaptic structure is dependent on a DLK-headed
transcriptional program. I further demonstrated that the neurotoxicity of pharmacological PP2A
inhibition in cultured mammalian cortical neurons is also a DLK-dependent process. Indeed, the
increase in Tau phosphorylation is independent from the cell death and from DLK signaling.
Together, these findings provide insight into a disease-relevant process and provide evidence for
DLK as a therapeutic target.

3.1 DLK and the cytoskeleton
Loss of PP2A function has been well-documented to cause cytoskeletal dysregulation
through multiple mechanisms. DLK signaling has been demonstrated to be activated by alteration
to cytoskeletal structure or function in specified contexts, including here with PP2A inhibition.
However, it remains unclear what about cytoskeletal dysregulation is activating DLK signaling.
Further, does increased DLK signaling affect cytoskeletal structure and function? Are we able to
identify a subset of genes regulated by the transcriptional program that affect the cytoskeleton and
are they sufficient to suppress synaptic overgrowth or cell death phenotypes?
Neuronal insults where the cytoskeleton is dysregulated converge on DLK stress signaling,
but these have not been shown to require cytoskeleton dysregulation to activate DLK(Valakh et
al., 2015b, 2013, 2012). PP2A acts on several substrates and signal transduction mechanisms, so
while the cytoskeleton is affected it is possible that PP2A signaling dampens DLK activation
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through another mechanism. To test this, one could attempt to stabilize the cytoskeleton while
inhibiting PP2A. This could be done genetically in the Drosophila system or pharmacologically
with cortical neurons. Overexpression of the spectraplakin Short Stop or the neuronal MAP Futsch
provide excellent candidates to stabilize the cytoskeleton(Roos et al., 2000; Valakh et al., 2013).
Short Stop is particularly attractive as it affects both microtubules and actin, and it remains unclear
if one aspect of the cytoskeleton more strongly affects DLK activation. The actin stabilizing drug
Jasplakinolide was sufficient to restore the membrane-associated periodic structure, a cytoskeletal
arrangement of microtubules and actin in the axon, following neurotrophic depletion and reduced
the DLK-dependent p-Jun induction in this model(Wang et al., 2019). Thus, this treatment seems
a likely candidate to stabilize the cytoskeleton when PP2A is inhibited and test whether levels of
p-MKK4, a readout of DLK activation, drop when cells are co-treated with PP2A inhibitor and
Jasplakinolide. If either of these systems work to reduce DLK signaling in the presence of PP2A
inhibition, follow up studies will have to be done to confirm a stabilization of the cytoskeleton and
test whether the membrane-associated periodic structure is affected by PP2A inhibition and intact
following stabilizing treatment.
The neuronal cytoskeleton is well-defined as being disrupted following PP2A inhibition
and I have demonstrated here that some of the downstream effects of PP2A inhibition are DLKdependent. However, I have not yet tested whether loss of DLK signaling reduces cytoskeletal
dysregulation. As a first step to explore this one could use the previously employed quantitative
measures of cytoskeletal stability, such as EB1-GFP comets, to test for whether DLK inhibition
affects cytoskeletal stability in neurons with lowered PP2A activity compared to those with intact
DLK signaling. The proposed experiments would test the hypothesis that DLK signaling, being
activated by a dysregulated cytoskeleton, acts in a negative feedback loop to stabilize the
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cytoskeleton. If this hypothesis was supported one would expect that neurons with PP2A inhibited
but DLK signaling intact would display some level of increased cytoskeletal stability compared to
neurons with both PP2A and DLK inhibited. Alternatively, it is also plausible that loss of DLK
signaling will increase cytoskeletal stability as the downstream phenotypes of PP2A inhibition,
such as synaptic overgrowth at the Drosophila NMJ, were previously posited to be caused by a
lack of cytoskeletal support and I have shown here that a reduction in DLK signaling suppresses
these phenotypes(Viquez et al., 2009). Thus, one would predict that neurons with PP2A and DLK
both inhibited have a more stable cytoskeleton than those with increased DLK signaling.
Lastly, it remains unclear exactly which genes in the DLK-controlled transcriptional
program are required for the observed phenotypes following PP2A inhibition. Our lab has
performed a microarray screen for genes that are upregulated following sciatic nerve injury in
mice, but whose induction is blocked in DLK knockout animals(Shin et al., 2019). The resulting
genes are defined as being part of a DLK-dependent transcriptional program. While these two
insults, sciatic nerve crush and PP2A inhibition, are distinct, the genes defined in this study provide
a probable first set of genes to test. If DLK-dependent phenotypes from PP2A inhibition are the
result of a single gene that would be relatively simple to test for suppression. However, it seems
likely that several genes involved in cellular processes will be alternatively regulated following
PP2A inhibition. Hence, it may be more prudent to start testing whether the same genes are
differentially regulated following PP2A inhibition as in sciatic nerve crush and following up on
any differences between the two paradigms.

3.2 PP2A modulation
In these studies, I have inhibited PP2A using the catalytic subunit. This inhibits all PP2A
forms, but there is a remarkable complexity in this holoenzyme in combinations of regulatory
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subunits(Janssens and Goris, 2001). Is there a specificity to which forms of PP2A are required for
restraining DLK signaling? PP2A function was also only inhibited directly in these studies, but
this is a tightly regulated protein. Do the same proteins modulating PP2A activity in AD patients
and disease models inhibit PP2A such that the downstream phenotypes are DLK-dependent?
Expression and incorporation of PP2A A and B regulatory subunits varies drastically
depending on cell type, point in development, and even cellular localization(Janssens and Goris,
2001). Because I have inhibited the catalytic subunit of PP2A in all experiments, either genetically
in Drosophila or pharmacologically in mammalian neurons, I cannot say whether a specific
subunit of PP2A is involved in reducing DLK signaling. The simplest way one could test whether
loss of a single regulatory subunit is sufficient to lose control of DLK signaling would be to screen
knockdown of regulatory subunits in Drosophila neurons for synaptic overgrowth or PucLacZ
induction. If any were found one could then test whether genetic knockdown in cortical neurons
also affected DLK activation. It is possible that these two cell types would have different regulatory
subunits modulating phenotypes, but flies present an ideal system for a small genetic screen. Any
insight into differences between which PP2A subunits are required for DLK restraint in peripheral
nervous system versus central nervous system would also provide a basis for further investigation
into any differences in DLK activation triggers between cell types. Loss of the B’ subunit wellrounded in Drosophila causes a decrease in synaptic boutons(Viquez et al., 2006). Previously,
activation of DLK/Wnd signaling has only been observed to increase synaptic bouton number, but
the fact that there is a change in synaptic morphology in these animals warrants testing whether
DLK signaling is affected. B’ subunit PR61 knockout mice have increased levels of
hyperphosphorylated Tau and demonstrate sensorimotor impairment(Louis et al., 2011). Together,
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these studies support the hypothesis that specific PP2A regulatory subunits are involved
downstream phenotypes.
It also remains unclear whether inhibition of all PP2A activity is required for DLK
activation, or whether a more nuanced regulation of signaling is sufficient. In AD patient brains
total levels of PP2A-C protein and expression are lowered, but there are also changes to other
proteins regulating PP2A(E et al., 2004; Sontag and Sontag, 2014; Vogelsberg-Ragaglia et al.,
2001b). Understanding if inhibition of PP2A through these changes in regulatory proteins also
activate DLK signaling would provide further evidence that DLK activation is a disease-relevant
process in AD patients. One could test this by asking whether p-MKK4 increases following I2PP2A
overexpression, PPMT knockdown, treatment with truncated α4, cancerous inhibitor of PP2A
(cip2A) overexpression, or LCMT-1 knockdown(Park et al., 2018; Shentu et al., 2018; Tanimukai
et al., 2005; Watkins et al., 2012b). All these manipulations have been observed in AD patient
brains and have been proposed to contribute to disease pathology through modulation of PP2A
activity.

3.3 PP2A targets
Here, I have shown that PP2A inhibition increases cortical neuron death independent from
Tau despite hyperphosphorylation of Tau being one of the best studied consequences of PP2A
inhibition in neurons. This finding demonstrates that hyperphosphorylated Tau does not affect a
cell-autonomous apoptosis pathway and that inhibition of DLK is required to block neuronal cell
death downstream of PP2A inhibition. Our system for assessing cell death only cultured cortical
neurons, but there is a vast literature demonstrating glial and immune response in AD. Could
hyperphosphorylated Tau contribute to cell death and disease progression in a non-cell
autonomous manner? Does DLK inhibition also affect this mechanism of degeneration? We have
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also focused on Tau as a single substrate of PP2A and suspect that modulation of a family of MAPs
is affected. Is it possible to define some of these downstream targets that contribute to DLK
activation when PP2A is inhibited?
The finding that neurons lacking any Tau protein show similar cell death rates to neurons
with normal levels of Tau protein and an increase in hyperphosphorylated Tau provided paradigmshifting evidence that increased Tau phosphorylation is not itself toxic. However, these findings
must be appreciated in the context of cell-autonomous apoptosis. Tau is not only aggregated
intracellularly, but also released into the extracellular space where it can be taken up by
surrounding cells, such as microglia, or contribute to the cell-to-cell spread of pathological Tau
species(Calafate et al., 2015; Gómez-Ramos et al., 2006; Pooler et al., 2013; Simón et al., 2012).
Because Tau extends beyond cell-autonomous functions, further testing should demonstrate
whether neuronal cell death following PP2A inhibition is still Tau-independent in systems better
representing the brain environment. One could test this using direct injection of PP2A inhibitor
into the mouse brain or a co-culture system with glial cells in addition to neurons and measuring
whether Tau knockout affects rates of cell death. If a Tau-dependent cell death process is found, it
should be examined whether DLK signaling affects such a process.
For this study I focused specifically on Tau as a PP2A substrate as it is well-studied and
disease relevant. However, PP2A targets many substrates, a number of them cytoskeleton-related
proteins. This provides a basis for further exploration into other DLK-dependent phenotypes
downstream of dysregulation of these proteins. For example, Doublecortin mutations have been
shown to cause X-linked lissencephaly. A mutated form of Doublecortin could be expressed in
Drosophila or cortical neurons to test for DLK activation and whether any phenotypes are DLKdependent(Schaar et al., 2004). We are also in the process of investigating the CLIP-associated
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protein Chromosome Bows (ChB) in Drosophila. ChB is a target of PP2A modulation in other cell
types and loss of function mutants present with synaptic overgrowth, thus this is a prime candidate
to test for DLK-dependent phenotypes(Galjart, 2005.; Inoue et al., 2000; Lee et al., 2004; Lemos
et al., 2000). It is likely that PP2A is modulating a family of cytoskeleton-associated proteins and
that no single protein will be required for downstream phenotypes in neurons with inhibited PP2A,
but substrates could provide candidates for a future screen testing for phenotypes that are DLKdependent.
There are other cytoskeleton-related proteins not as directly related to PP2A that may also
serve as candidates for a screen of DLK function. Depletion of the microtubule severing protein
Katanin causes an increase in synaptic bouton number at the larval NMJ, a similar phenotype to
flies overexpressing DLK/Wnd or mutant for the E3 ubiquitin ligase highwire which targets Wnd
for degradation(Collins et al., 2006; Yu et al., 2008). Spastin, a related microtubule severing
protein, is mutated people suffering from hereditary spastic paraplegia. In this degenerative disease
patients experience weakness and spasticity in their lower limbs as long axon tracts
degenerate(Fink, 2013). This increased neuronal stress and axon degeneration are candidates for
DLK-dependent processes. Thus, microtubule severing enzymes present an intriguing set of targets
for a screen to test if their loss of function triggers an increase in DLK signaling.

3.4 Conclusion
Neurons must survive a lifetime and so have complex signal transduction mechanisms to
interpret internal and external stressors. PP2A acts to restrain stress signaling through the DLK
pathway in neurons, both during development and in degenerative disease. The synaptic
overgrowth at the neuromuscular junction in animals with decreased PP2A activity requires a
transcriptional program and is not directly caused by a lack of cytoskeletal support for the
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developing neuron as had been previously hypothesized. The discovery of a cell-autonomous
response headed by DLK provided insight into the mechanism of cell death following neuronal
PP2A inhibition and defined a target for therapeutic intervention in a devastating disease. Further,
I demonstrated that Tau is not required for a cell intrinsic apoptotic pathway despite the link
between phosphorylation status of Tau and PP2A activity being a focus of research for decades.
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